close

NeurogesX, Inc., a development stage biopharmaceutical company, focuses on developing and commercializing novel pain management therapies. The company's lead product candidate Qutenza, a dermal patch containing synthetic capsaicin, completed its phase III clinical trials to manage pain associated with peripheral neuropathic pain conditions; completed two phase III trials for HIV-distal sensory polyneuropathy; and is in the U.S. open label phase II data for painful diabetic neuropathy. Its product candidates in pipeline include NGX-1998, a non-patch liquid formulation of capsaicin for potential use in neuropathic pain conditions; NGX-1576, NGX-9674, and NGX-5752 prodrugs of acetaminophen for potential use in acute pain, including traumatic pain, post-surgical pain, and fever; and NGX-6052, an opioid prodrug for potential use in chronic pain indications. The company was formerly known as Advanced Analgesics, Inc. and changed its name to NeurogesX, Inc. in September 2000. NeurogesX, Inc. was founded in 1998 and is headquartered in San Mateo, California.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	0.62
Volume	(mio) 1.14
Volume Avg	319979
52 Week High	4.47
52 Week Low	0.47
PE	N/A
PE (group average)	N/A
EPS Year	-2.15
EPS change Q/Q	-8.7%
EPS change Q/Q Yr ago	-44.23%
EPS change Q/Q next Q est	-141.94%
EPS change Y/Y	-45.26%
REV change Q/Q	39.13%
REV change Q/Q Yr ago	77.78%
EPS next Q est	-0.31
EPS next Y est	-0.82
Divident Annual	0.00
Dividend Yield	0%